Acroda Therapeutics is a biotechnology company based out of Ardsley, New York that was founded in 1995 by Ron Cohen. The company is working to develop and commercialize treatments for neurological disorders of the central nervous system such as multiple sclerosis, spinal cord injuries, and Parkinson's disease.
On January 19, 2016 Acorda Therapeutics acquired Biotie Therapies for $25.60 per share for a total of approximately $363 million. Acorda Therapeutics bought Biotie Therapies to acquire two of its drug candidates for the treatment of Parkinson's disease called Tozadenant and SYN120.
Chief Scientific Officer
Chief Business Officer
Chief Medical Officer
Chief Business Operations and Principal accounting Officer
Executive Vice President
President of International & General Counsel
Chief Commercial Officer
Founder, President & CEO
Executive Vice President of Corporate Communications
Acorda Therapeutics investor calls for company to explore sale
Acorda Therapeutics stock rises on closure of FDA inspections
What's Behind Acorda Therapeutics Crashing 24.5% Today -- The Motley Fool
Documentaries, videos and podcasts